1. Home
  2. BIPC vs BLTE Comparison

BIPC vs BLTE Comparison

Compare BIPC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brookfield Infrastructure Corporation

BIPC

Brookfield Infrastructure Corporation

BUY

Current Price

$37.38

Market Cap

4.6B

ML Signal

BUY

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$154.78

Market Cap

6.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIPC
BLTE
Founded
2019
2018
Country
United States
United States
Employees
250000
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
6.6B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
BIPC
BLTE
Price
$37.38
$154.78
Analyst Decision
Sell
Strong Buy
Analyst Count
1
7
Target Price
$45.00
$198.00
AVG Volume (30 Days)
989.1K
112.2K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
5.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.85
N/A
Revenue Next Year
$5.94
$492.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.18
$56.68
52 Week High
$51.72
$200.00

Technical Indicators

Market Signals
Indicator
BIPC
BLTE
Relative Strength Index (RSI) 35.85 41.83
Support Level N/A $148.06
Resistance Level $40.93 $161.28
Average True Range (ATR) 1.37 6.15
MACD -0.34 -1.15
Stochastic Oscillator 37.42 8.53

Price Performance

Historical Comparison
BIPC
BLTE

About BIPC Brookfield Infrastructure Corporation

Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom, United States, France, Switzerland, Singapore, China, Denmark, Hong Kong, Germany and Others.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: